The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
 
Curtis Andrew Lachowiez
No Relationships to Disclose
 
Gautam Borthakur
Consulting or Advisory Role - Argenx; BiolineRx; BioTheryX; Nkarta; PTC Therapeutics; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Arvinas (Inst); AstraZeneca (Inst); BiolineRx (Inst); BioTheryX (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); MedImmune (Inst); Mundipharma Research (Inst); Novartis (Inst); Oncoceutics (Inst); PTC Therapeutics (Inst); Ryvu Therapeutics (Inst); XBiotech (Inst)
 
Sanam Loghavi
No Relationships to Disclose
 
Zhihong Zeng
No Relationships to Disclose
 
Tapan M. Kadia
Consulting or Advisory Role - Abbvie/Genentech; Jazz Pharmaceuticals; Novartis; Pfizer
Research Funding - Amgen; BiolineRx; Bristol-Myers Squibb; Celgene; Genentech/Abbvie; Incyte; Incyte; Jazz Pharmaceuticals; Pfizer; Pfizer; Sanofi
 
Lucia Masarova
No Relationships to Disclose
 
Koichi Takahashi
No Relationships to Disclose
 
George Dono Tippett
No Relationships to Disclose
 
Kiran Naqvi
No Relationships to Disclose
 
Prithviraj Bose
Honoraria - Blueprint Medicines; Celgene; CTI BioPharma Corp; Incyte; Kartos Therapeutics
Consulting or Advisory Role - Incyte
Speakers' Bureau - Incyte
Research Funding - Astellas Pharma (Inst); Blueprint Medicines (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Kartos Therapeutics (Inst); NS Pharma (Inst); Pfizer (Inst); Promedior (Inst)
Travel, Accommodations, Expenses - Celgene; Incyte
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Pfizer; Takeda
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Celgene; Orsenix; Pfizer; Seattle Genetics; Sunesis Pharmaceuticals
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Celgene; Jazz Pharmaceuticals; Orsenix; Seattle Genetics; Sunesis Pharmaceuticals
Research Funding - Amgen; Bristol-Myers Squibb; Cellerant; Macrogenics; Merck; Seattle Genetics; Selvita; Sunesis Pharmaceuticals; Xencor
 
Naval Guastad Daver
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Immunogen; Incyte; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer
Research Funding - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Immunogen; Nohla Therapeutics; Pfizer; Servier
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Celgene; Helssin
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb; Celgene; Helsinn Therapeutics; Jazz Pharmaceuticals
Research Funding - Abbvie; Amphivena; Astex Pharmaceuticals; Bristol-Myers Squibb; celgene; H3 Biomedicine; Helsinn Therapeutics; Merck; Novartis; Onconova Therapeutics
 
Bilyana Stoilova
No Relationships to Disclose
 
Paresh Vyas
Stock and Other Ownership Interests - OxStem
Honoraria - Abbvie; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Pfizer
Research Funding - Celgene; Forty Seven
Patents, Royalties, Other Intellectual Property - Patent for flow cytometric detection of leukaemic stem cells
 
Hagop M. Kantarjian
Honoraria - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; ARIAD; Bristol-Myers Squibb; Immunogen; Orsenix; Pfizer; Takeda
Research Funding - Abbvie (Inst); Agios (Inst); Agios (Inst); Agios (Inst); Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst)
 
Marina Konopleva
Honoraria - Abbvie; Genentech; Roche
Consulting or Advisory Role - AbbVie; Genentech/Roche
Research Funding - Abbvie (Inst); Genentech (Inst); Roche (Inst)
 
Courtney Denton Dinardo
Leadership - Notable Labs
Honoraria - Abbvie; Agios; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; MedImmune; Syros Pharmaceuticals
Consulting or Advisory Role - Abbvie; Agios; Celgene
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo
 
Anna B. Halpern
No Relationships to Disclose